Goldman Sachs’s Cardio Diagnostics CDIO Stock Holding History
Bought
Maintained
Sold
Other funds holding CDIO
LA
PAMP
YCM
CCM
ASM
BFM
CSC
Goldman Sachs's CDIO Position: Q4 2022 in Review
Goldman Sachs sold out of Cardio Diagnostics (CDIO) in Q4 2022, closing a stake of 2,387 shares — an estimated $718K sold.
Goldman Sachs first reported a position in CDIO in Q1 2022 and held it in 3 quarters. The position peaked at $718K in Q3 2022. 11 funds tracked by Wall St. Rank hold CDIO as of Q4 2022.
- Goldman Sachs reported no remaining Cardio Diagnostics position as of Q4 2022 after selling out during the quarter.
- Goldman Sachs sold 2,387 Cardio Diagnostics shares in Q4 2022, an estimated $718K.
- Goldman Sachs first reported a position in Cardio Diagnostics in Q1 2022 and held it in 3 quarters.
- Goldman Sachs's Cardio Diagnostics position peaked at $718K in Q3 2022.
- 11 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q4 2022.
Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.